This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldenberg-Furmanov, M. Articles by Ben-Sasson, S. A. Search for Related Content PubMed PubMed Citation Articles by Goldenberg-Furmanov, M. Articles by Ben-Sasson, S. A.

Lyn Is a Target Gene for Prostate Cancer

Sequence-Based Inhibition Induces Regression of Human Tumor Xenografts

Departments of ¹ Experimental Medicine and Cancer Research, ² Pathology, and ³ Oncology, The Hebrew University-Hadassah Medical School, and ⁴ Keryx Biopharmaceuticals, Jerusalem, Israel

The Src-related protein kinase Lyn plays an important role in B-cell activation. However, several lines of evidence suggest that it is also involved in the control of cellular proliferation and the inhibition of apoptosis. We have discovered that Lyn is expressed in normal prostate epithelia, in 95% of primary human prostate cancer (PC) specimens examined, and in all of the PC cell lines that we assayed. Moreover, Lyn knockout mice display abnormal prostate gland morphogenesis, which suggests that Lyn plays an important role in prostate epithelium development and implies that Lyn is a candidate target for specific therapy for PC. Using a drug-design strategy to construct sequence-based peptide inhibitors, a Lyn-specific inhibitor, KRX-123, targeting a unique interaction site within Lyn, was synthesized. KRX-123 was found to inhibit cellular proliferation in three hormone-refractory PC cell lines, DU145, PC3, and TSU-Pr1 with IC₅₀ values of 2–4 µM. In vivo, tumor volume of DU145 explants in nude mice was significantly reduced after once-a-week injections of KRX-123, at a dose of 10 mg/kg, for a period of 5 weeks. Histological analyses of the treated tumors indicated extensive apoptosis. Thus, we suggest that Lyn inhibition may serve as a prime target for the treatment of hormone-refractory PC.

This article has been cited by other articles:

				H. Guan, Z. Zhou, G. E. Gallick, S.-F. Jia, J. Morales, A. K. Sood, S. J. Corey, and E. S. Kleinerman Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma Mol. Cancer Ther., July 1, 2008; 7(7): 1807 - 1816. [Abstract] [Full Text] [PDF]

				L. J. Inge, S. A. Rajasekaran, D. Wolle, S. P. Barwe, S. Ryazantsev, C. M. Ewing, W. B. Isaacs, and A. K. Rajasekaran {alpha}-Catenin overrides Src-dependent activation of {beta}-catenin oncogenic signaling Mol. Cancer Ther., June 1, 2008; 7(6): 1386 - 1397. [Abstract] [Full Text] [PDF]

				R. Cheung, V. Ravyn, L. Wang, A. Ptasznik, and R. G. Collman Signaling Mechanism of HIV-1 gp120 and Virion-Induced IL-1{beta} Release in Primary Human Macrophages J. Immunol., May 15, 2008; 180(10): 6675 - 6684. [Abstract] [Full Text] [PDF]

				S. I. Park, J. Zhang, K. A. Phillips, J. C. Araujo, A. M. Najjar, A. Y. Volgin, J. G. Gelovani, S.-J. Kim, Z. Wang, and G. E. Gallick Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model Cancer Res., May 1, 2008; 68(9): 3323 - 3333. [Abstract] [Full Text] [PDF]

				K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				J M W Gee, V E Shaw, S E Hiscox, R A McClelland, N K Rushmere, and R I Nicholson Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S77 - S88. [Abstract] [Full Text] [PDF]

				B. Tomkowicz, C. Lee, V. Ravyn, R. Cheung, A. Ptasznik, and R. G. Collman The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages Blood, August 15, 2006; 108(4): 1145 - 1150. [Abstract] [Full Text] [PDF]

				Y. Nakata, B. Tomkowicz, A. M. Gewirtz, and A. Ptasznik Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells Blood, June 1, 2006; 107(11): 4234 - 4239. [Abstract] [Full Text] [PDF]

				L. Xin, M. A. Teitell, D. A. Lawson, A. Kwon, I. K. Mellinghoff, and O. N. Witte Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor PNAS, May 16, 2006; 103(20): 7789 - 7794. [Abstract] [Full Text] [PDF]

				S. Nam, D. Kim, J. Q. Cheng, S. Zhang, J.-H. Lee, R. Buettner, J. Mirosevich, F. Y. Lee, and R. Jove Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells Cancer Res., October 15, 2005; 65(20): 9185 - 9189. [Abstract] [Full Text] [PDF]

				C.-L. Chu and C. A. Lowell The Lyn Tyrosine Kinase Differentially Regulates Dendritic Cell Generation and Maturation J. Immunol., September 1, 2005; 175(5): 2880 - 2889. [Abstract] [Full Text] [PDF]